Celularity (NASDAQ:CELUW) Stock Price Up 264.7% – Should You Buy?

Celularity Inc. (NASDAQ:CELUWGet Free Report) shares rose 264.7% during mid-day trading on Friday . The stock traded as high as $0.75 and last traded at $0.12. Approximately 77,893 shares changed hands during trading, an increase of 165% from the average daily volume of 29,443 shares. The stock had previously closed at $0.03.

Celularity Trading Up 264.7 %

The firm has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.03.

About Celularity

(Get Free Report)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

See Also

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.